FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4247144756> ?p ?o ?g. }

• W4247144756 endingPage "2350" @default.
• W4247144756 startingPage "2350" @default.
• W4247144756 abstract "Abstract Background: Over the past 2 decades, treatment advances have greatly improved the outcomes of patients with multiple myeloma (MM) and a glut of new knowledge about the biology, genetic profile, and prognostic factors of the disease have become available. However, much of this research has excluded patients with low performance status and those with impaired renal function or marrow reserve, therefore, relatively little is known about these patients who are largely ineligible for clinical trials. We performed a secondary data analysis of the Multiple Myeloma Research Foundation (MMRF) CoMMpass study to compare the disease manifestation, treatment, and prognosis of these patients with the overall MM population. Methods: Data was extracted from the open-access MMRF Researcher Gateway corresponding with interim analysis 8 from the CoMMpass study. The CoMMpass study is enrolling 1000 newly diagnosed MM patients who will be tracked longitudinally for 5 years. CoMMpass collects relevant clinical data as well as sequential tissue samples. Eligibility requirements for CoMMpass include: symptomatic MM with measureable disease by SPEP (≥1.0g/dL), UPEP (≥200mg/24 hours), or SFLC (≥10mg/dL); receiving an immunomodulator (IMID) and/or a proteasome inhibitor (PI) for initial MM treatment; and no prior malignancies in the past 5 years. We defined ineligibility for clinical trials as one or more of the following at time of MM diagnosis: ECOG performance status 3 or 4; creatinine ≥ 2.0mg/dL or receiving dialysis; absolute neutrophil count (ANC) <1.0x109/L or receiving growth factor support; or platelet count <50,000 x109/L or receiving platelet transfusion support. We compared the demographics, baseline presentation (International Staging System [ISS] stage, marrow and extramedullary disease burden, and chromosomal abnormalities), and first-line treatment of these patients with the overall population using bivariate analyses. We then performed a multivariate Cox regression analysis to compare event-free survival (EFS) defined as the interval from diagnosis to disease progression or death. The level of significance was set at 0.05 for all tests. Results: 799 patients were available for analysis. The median age was 64 years, 61% (486) were male, and 76% (611) were white. 23% (180) met the study definition of ineligibility for clinical trials. 5% (41/778) had low performance status, 16% (128/799) impaired renal function, 3% (22/799) impaired marrow reserve. Patients ineligible for clinical trials were similar to the rest of the population demographically, but were more likely have higher risk disease by ISS (70% stage 3 compared to 20%, p <0.0001), and deletion of 17p (11% compared to 6%, p <0.0298), and were less likely to receive IMIDs during first-line therapy (35% compared to 64%, p <0.0001). Interestingly, stem cell transplant (SCT) utilization was similar between the two groups (32% compared to 34%, p >0.05). Bivariate analyses are summarized in Table 1. After controlling for ISS stage, deletion of 17p, first-line treatment, and SCT utilization, patients ineligible for clinical trials had a 56% (aHR 1.56 [95% CI 1.09- 2.23], p = 0.0141) increase in risk of disease progression or death. Conclusion: Newly diagnosed MM patients with low performance status, impaired renal function, or marrow reserve have long been considered a high-risk group and, thus, most clinical trials have excluded them. IMIDs are contraindicated for these patients due to its myelotoxicity which further limits treatment options. After adjusting for differences in treatment, these patients still have poorer outcomes. Additional research is needed to better understand the needs of these patients and improve their outcomes. Table 1 Table 1. Disclosures Vij: Karyopharma: Consultancy; Bristol-Myers Squibb: Consultancy; Takeda: Consultancy, Research Funding; Amgen: Consultancy, Research Funding; Celgene: Consultancy; Janssen: Consultancy; Novartis: Consultancy; Jazz: Consultancy; Shire: Consultancy." @default.
• W4247144756 created "2022-05-12" @default.
• W4247144756 creator A5021003906 @default.
• W4247144756 creator A5026151069 @default.
• W4247144756 creator A5027582479 @default.
• W4247144756 creator A5036363023 @default.
• W4247144756 creator A5082072227 @default.
• W4247144756 creator A5090424930 @default.
• W4247144756 date "2016-12-02" @default.
• W4247144756 modified "2023-09-30" @default.
• W4247144756 title "The Real-World Characteristics and Outcomes of Newly Diagnosed Myeloma Patients Ineligible for Clinical Trials" @default.
• W4247144756 doi "https://doi.org/10.1182/blood.v128.22.2350.2350" @default.
• W4247144756 hasPublicationYear "2016" @default.
• W4247144756 type Work @default.
• W4247144756 citedByCount "3" @default.
• W4247144756 countsByYear W42471447562017 @default.
• W4247144756 countsByYear W42471447562019 @default.
• W4247144756 countsByYear W42471447562021 @default.
• W4247144756 crossrefType "journal-article" @default.
• W4247144756 hasAuthorship W4247144756A5021003906 @default.
• W4247144756 hasAuthorship W4247144756A5026151069 @default.
• W4247144756 hasAuthorship W4247144756A5027582479 @default.
• W4247144756 hasAuthorship W4247144756A5036363023 @default.
• W4247144756 hasAuthorship W4247144756A5082072227 @default.
• W4247144756 hasAuthorship W4247144756A5090424930 @default.
• W4247144756 hasConcept C126322002 @default.
• W4247144756 hasConcept C141071460 @default.
• W4247144756 hasConcept C143998085 @default.
• W4247144756 hasConcept C2776063141 @default.
• W4247144756 hasConcept C2776364478 @default.
• W4247144756 hasConcept C2908647359 @default.
• W4247144756 hasConcept C535046627 @default.
• W4247144756 hasConcept C61943457 @default.
• W4247144756 hasConcept C71924100 @default.
• W4247144756 hasConcept C99454951 @default.
• W4247144756 hasConceptScore W4247144756C126322002 @default.
• W4247144756 hasConceptScore W4247144756C141071460 @default.
• W4247144756 hasConceptScore W4247144756C143998085 @default.
• W4247144756 hasConceptScore W4247144756C2776063141 @default.
• W4247144756 hasConceptScore W4247144756C2776364478 @default.
• W4247144756 hasConceptScore W4247144756C2908647359 @default.
• W4247144756 hasConceptScore W4247144756C535046627 @default.
• W4247144756 hasConceptScore W4247144756C61943457 @default.
• W4247144756 hasConceptScore W4247144756C71924100 @default.
• W4247144756 hasConceptScore W4247144756C99454951 @default.
• W4247144756 hasIssue "22" @default.
• W4247144756 hasLocation W42471447561 @default.
• W4247144756 hasOpenAccess W4247144756 @default.
• W4247144756 hasPrimaryLocation W42471447561 @default.
• W4247144756 hasRelatedWork W2133569604 @default.
• W4247144756 hasRelatedWork W2136773918 @default.
• W4247144756 hasRelatedWork W2274063048 @default.
• W4247144756 hasRelatedWork W2344741804 @default.
• W4247144756 hasRelatedWork W2744415914 @default.
• W4247144756 hasRelatedWork W2946012186 @default.
• W4247144756 hasRelatedWork W2957963791 @default.
• W4247144756 hasRelatedWork W3121407702 @default.
• W4247144756 hasRelatedWork W3198246197 @default.
• W4247144756 hasRelatedWork W4283376564 @default.
• W4247144756 hasVolume "128" @default.
• W4247144756 isParatext "false" @default.
• W4247144756 isRetracted "false" @default.
• W4247144756 workType "article" @default.